We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of $3.99. The bottom line declined 5.2% ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...